EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023
31 Outubro 2023 - 8:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to improve the lives
of patients with retinal diseases, today announced it will host a
virtual key opinion leader (KOL) event on Thursday, November 9,
2023 from 8:00 to 9:00 am ET.
This event will focus on the potential of
EYP-1901 in wet age-related macular degeneration (wet AMD),
including KOL perspectives on the current wet AMD treatment
landscape, vorolanib’s unique mechanism of action and outcome
considerations for the upcoming topline data read-out for the DAVIO
2 trial in December. The event will be moderated by EyePoint’s
President and Chief Executive Officer, Jay S. Duker, M.D., and will
feature presentations from the following retinal experts:
- David S. Boyer,
M.D., Senior Partner at Retina-Vitreous Associates Medical
Group, Adjunct Clinical Professor of Ophthalmology at University of
Southern California, Keck School of Medicine
- David R. Lally,
M.D., Retinal Surgeon at Baystate Medical Center,
Assistant Professor of Ophthalmology at the University of
Massachusetts Medical School-Baystate, Director of Retina Research
Institute at New England Retinal Consultants
To access the live conference call, please
register using the audio conference link:
https://register.vevent.com/register/BI7011e8a8a96a408b91e23c1c3f598ede.
A live audio webcast of the event can be accessed via the Investors
section of the Company website at www.eyepointpharma.com. A webcast
replay will also be available on the corporate website at the
conclusion of the call.
About EYP-1901
EYP-1901 is being developed as an
investigational sustained delivery treatment for retinal disease
combining a bioerodible formulation of EyePoint's proprietary
Durasert® delivery technology (Durasert E™) with vorolanib, a
tyrosine kinase inhibitor. Results from the Phase 1 DAVIO clinical
trial of EYP-1901 in wet AMD showed a positive safety profile with
stable visual acuity and OCT. Further, the data demonstrated an
impressive treatment burden reduction of 75% at six months and 73%
at the 12-month visit following a single dose of EYP-1901. Phase 2
trials are fully enrolled in wet AMD and non-proliferative diabetic
retinopathy, and a diabetic macular edema trial is planned for
initiation in Q1 2024. Vorolanib is licensed to EyePoint
exclusively by Equinox Sciences for the localized treatment of all
ophthalmic diseases.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
company committed to developing and commercializing therapeutics to
help improve the lives of patients with retinal diseases. The
Company's pipeline leverages its proprietary bioerodible Durasert
E™ technology for sustained intraocular drug delivery including
EYP-1901, an investigational sustained delivery intravitreal
anti-VEGF treatment currently in Phase 2 clinical trials. The
proven Durasert® drug delivery platform has been safely
administered to over 80,000 patient eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts. For more information visit
www.eyepointpharma.com.
Investors:Christina
TartagliaStern IRDirect:
212-698-8700christina.tartaglia@sternir.com
Media Contact:Amy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024